To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.
Also called NCT07116473
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 250 participants
- Registry
-
NCT07116473
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07116473. Allocation not applicable; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2037-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Condition
- Amyloidosis in Transthyretin (TTR)
- Condition
- Amyloidosis, Familial
- Condition
- Amyloid Cardiomyopathy
- Condition
- Amyloid Cardiomyopathy, Transthyretin-Related
- Condition
- Amyloidogenic Transthyretin (ATTR) Amyloidosis
- Condition
- Heart Disease
- Condition
- Cardiomyopathies
- Condition
- Amyloidosis, Hereditary, Transthyretin-Related
- Condition
- Polyneuropathies
- Condition
- Amyloidosis
- Intervention (Drug)
- Acoramidis (AG10)
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
Record details
- Record id
cardio:ct-nct07116473- Content hash
99985d70537c15093f40ee3929752249da4631f2679d0ae543d1b355e6d3947d